Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Crude falls as Saudis offer more supply, U.S. weighs SPR release

2018-07-16 worldoil
LONDON (Bloomberg) -- Oil retreated below $70/bbl as Saudi Arabia was said to offer extra crude to some customers, while the U.S. was said to consider tapping emergency supplies to offset losses elsewhere.
BNPZY BNPQY BNPQF

5
‘This Is Not a Passing Fad’: CFA Exam Adds Crypto, Blockchain Topics - Bloomberg

2018-07-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK GS.PRICL GSC BNPQY TFG GS.PRB GS.PRA BNPQF GSJ GS.PRJ GS.PRI GS BNPZY GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK

8
Diana Shipping Inc. Announces Signing and Drawdown of a US$75 Million Term Loan Facility With BNP Paribas

2018-07-16 globenewswire
ATHENS, Greece, July 16, 2018 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE:DSX), (the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, today announced that on July 13, 2018, it signed a term loan facility with BNP Paribas for up to US$75 million with maturity date on July 16, 2023. Today, it completed a drawdown of US$75 million, secured by the vessels m/v Alcmene, m/v Seattle, m/v Electra, m/v Phaidra, m/v Astarte, m/v G.
BNPZY BNPQY DSXN DSX BNPQF DSX.PRB

0
Beware the reach of Her Majesty's taxman, Brexit bankers told | Euronews

2018-07-16 euronews
LONDON (Reuters) – Financial workers weighing up offers to move to Europe after Brexit may find out that relocating is financially more complicated than they bargained for thanks to the long arm of Her Majesty’s Revenues and Customs (HMRC).
BNPZY DB MS.PRI MS.PRK BNPQY MS.PRE OML MS.PRF MS.PRG BNPQF MS MS.PRA

0
Beware the reach of Her Majesty's taxman, Brexit bankers told

2018-07-16 reuters
LONDON (Reuters) - Financial workers weighing up offers to move to Europe after Brexit may find out that relocating is financially more complicated than they bargained for thanks to the long arm of Her Majesty’s Revenues and Customs (HMRC).
BNPZY DB MS.PRI MS.PRK BNPQY MS.PRE OML MS.PRF MS.PRG BNPQF MS MS.PRA

0
MOVES-Exotix Capital hires execs to expand fixed income presence

2018-07-16 reuters
(Reuters) - Exotix Capital, the developing markets investment bank, said it has hired four new executives to expand its global presence in fixed income.
BNPZY UDBKL BNPQY UBLA UBLS BNPQF

0
Flash - Dutch court backs record 1.3 bn euro Ageas deal over Fortis - France 24

2018-07-14 france24
A Dutch court Friday ended a long-running saga over the 2008 dismantling of the Fortis bank insurance group, approving a record 1.3 billion euros ($1.5 billion) settlement deal for out-of-pocket shareholders.
BNPZY BNPQY BNPQF

0
BASF Playing China Matchmaker Should Worry U.S. - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
STAN BNPQY ULVR OGZD UNLNF HSB STAB STAC SCBFF STAN BFFAF HSBC.PRA HSBC SYT HBCYF HCS.PRB UL UN UNLYF BNPQF DDAIF HCS SYENF VLKAF 0005 BNPZY 580001 2888 HSEA HSEB BASFY BFA 81JK

0
Oil Prices Crash As Libya Resumes Production

2018-07-11 oilprice
Nick Cunningham is a freelance writer on oil and gas, renewable energy, climate change, energy policy and geopolitics. He is based in Pittsburgh, PA.
BNPZY BNPQY BNPQF

1
David Herro Market Commentary Q2 2018

2018-07-11 seekingalpha
Average Annual Total Returns (06/30/18) Since Inception (09/30/92) 9.85% 10–year 8.36% 5–year 6.83% 1–year 3.13% 3–month -5.04% Gross Expense Ratio as of 09/30/17 was 1.00% Net Expense Ratio as of 09/30/17 was 0.95%
CNHI BAMXF BNPZY BAMXY BMWYY BNPQY BYMOF BNPQF DDAIF

1
Oil falls as trade war escalates

2018-07-11 worldoil
LONDON (Bloomberg) -- Oil fell toward $73/bbl in New York after U.S. President Donald Trump escalated a trade war with China, heightening fears that global economic growth could be caught in the cross-fire.
BNPZY RDS.B RDS.A BNPQY RYDBF RDSB BNPQF RDSA RYDAF

0
Oil falls as trade war escalates, Libya plans to resume supply

2018-07-11 bworldonline
Oil fell below $74 a barrel after US President Donald Trump escalated a trade war with China, heightening fears that global economic growth could be caught in the cross-fire.
BNPZY BNPQY BNPQF

0
Brent oil falls more than US$2 after Trump tariff threat, Libya ports reopen

2018-07-11 theedgemarkets
LONDON (July 11): Global oil benchmark Brent fell more than US$2 a barrel on Wednesday after US President Donald Trump threatened to levy new tariffs on China and Libya announced the reopening of key oil export terminals.
BNPZY BNPQY BNPQF

0
Brent oil falls more than $2 after Trump tariff threat, Libya ports reopen

2018-07-11 reuters
LONDON (Reuters) - Global oil benchmark Brent fell more than $2 a barrel on Wednesday after U.S. President Donald Trump threatened to levy new tariffs on China and Libya announced the reopening of key oil export terminals.
BNPZY BNPQY BNPQF

0
Oil falls on trade fears after Trump tariff threat

2018-07-11 theedgemarkets
LONDON/TOKYO (July 11): Oil prices fell on Wednesday after U.S. President Donald Trump threatened to levy new tariffs on China, deepening a trade dispute that could depress energy demand.
BNPZY BNPQY BNPQF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 05565A202